Ortacta is a branded formulation of rivaroxaban, a direct oral anticoagulant (DOAC) that inhibits factor Xa. The 10 mg dose is often used for prevention of venous thromboembolism (VTE) postoperatively (e.g. after hip or knee replacement) or for extended prophylaxis in selected patients.
Price: ₵23.00 /Tablet
Prescription:Prescription-only (Rx). It must be prescribed by a qualified clinician due to bleeding risks. |
Therapeutic Category:Anticoagulant / Direct Factor Xa inhibitor |
Active Ingredients | Rivaroxaban 10 mg per tablet (active ingredient).
Excipients and the full composition vary by manufacturer (film coating, tablet core, etc.), as typical. |
Variant(s) | Other strengths / variants of Ortacta include 15 mg and 20 mg tablets. |
Consume Type | Oral tablet (film-coated) to be swallowed with water. |
Common Side Effects |
Package Type | Commonly sold in blister packs (e.g. 30 tablets) for Ortacta 10 mg. |
Storage Advice | Store below 30 °C (room temperature), protected from moisture and light. Keep in the original package to protect from light and humidity. |
Product Substitutes | Other rivaroxaban brands / generics (e.g. Xarelto)
Other oral anticoagulants (depending on indication) such as apixaban, dabigatran, edoxaban, warfarin (if appropriate) |
Manufacturer / Marketer | Ortacta is marketed by Acino (or associated licensing company) in certain markets. |
Country of Origin | While rivaroxaban is originally developed by Bayer (Germany), the “Ortacta” variant is registered in Ghana (FDA registration: FDA/SD.223-030362) |
Do you have any questions? Do not hesitate to contact us.
Reviews
There are no reviews yet.